Show simple item record

dc.contributor.authorKumarachandran, G.
dc.contributor.authorJohnson, J.K.
dc.contributor.authorShirley, D.-A.
dc.date.accessioned2019-07-15T16:12:12Z
dc.date.available2019-07-15T16:12:12Z
dc.date.issued2017
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85041000489&doi=10.5863%2f1551-6776-22.3.218&partnerID=40&md5=f5982498557c356c14ffe7d8c34a50a5
dc.identifier.urihttp://hdl.handle.net/10713/9936
dc.description.abstractOBJECTIVES Staphylococcus aureus bacteremia is a common infection, associated with significant morbidity and mortality in children. Factors associated with adverse treatment outcomes are poorly understood in the pediatric population. METHODS Our study compared clinical and microbiologic characteristics of children admitted during a 5-year period (2007�2012) to a large university-based hospital and found to have S aureus bacteremia with outcome measures, in order to identify risk factors associated with treatment failure (defined as 30-day mortality, delayed microbiologic resolution, or recurrence of S aureus bacteremia within 60 days of completing effective antibiotic therapy). RESULTS In all, 71 patients were found to have S aureus bacteremia, and of these, 17 patients (24%) experienced treatment failure. Based on the logistic regression model, only high vancomycin minimum inhibitory concentration in combination with a high-risk source of infection (i.e., infected graft or device, intra-abdominal infection, or respiratory tract infection) was significantly associated with risk of treatment failure. CONCLUSIONS Infection associated with a high-risk source may increase the chance of treatment failure in pediatric patients with S aureus bacteremia. Vancomycin minimum inhibitory concentration alone was not found to be a predictor of treatment outcomes. Copyright Published by the Pediatric Pharmacy Advocacy Group. All rights reserved.en_US
dc.description.urihttps://www.doi.org/10.5863/1551-6776-22.3.218en_US
dc.language.isoen_USen_US
dc.publisherPediatric Pharmacy Advocacy Group, Inc.en_US
dc.relation.ispartofJournal of Pediatric Pharmacology and Therapeutics
dc.subjectAdverse outcomeen_US
dc.subjectBacteremiaen_US
dc.subjectChildrenen_US
dc.subjectMICen_US
dc.subjectStaphylococcus aureusen_US
dc.subjectVancomycinen_US
dc.titlePredictors of adverse outcomes in children with Staphylococcus aureus Bacteremiaen_US
dc.typeArticleen_US
dc.identifier.doi10.5863/1551-6776-22.3.218


This item appears in the following Collection(s)

Show simple item record